Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorMATONTI, Frederic
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.contributor.authorDOT, Corinne
dc.contributor.authorGUALINO, Vincent
dc.contributor.authorSOLER, Vincent
dc.contributor.authorMREJEN, Sarah
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDELYFER, Marie-Noelle
dc.contributor.authorBAILLIF, Stephanie
dc.contributor.authorSTREHO, Mate
dc.contributor.authorGASCON, Pierre
dc.contributor.authorCREUZOT-GARCHER, Catherine
dc.contributor.authorKODJIKIAN, Laurent
dc.date.accessioned2022-05-16T12:07:07Z
dc.date.available2022-05-16T12:07:07Z
dc.date.issued2022-03-25
dc.identifier.issn2077-0383 (Print) 2077-0383 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140067
dc.description.abstractEnIntravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) have become the standard of care for age-related macular degeneration (AMD). Although most pivotal trials have used monthly injections, alternative strategies that enable the injections to be administered on a more flexible schedule, including pro re nata (PRN) and treat-and-extend (T&E) regimens, are being applied more frequently. This review sought to provide further scientific evidence about the visual outcomes and treatment burden among the currently available anti-VEGF agents and regimens, including aflibercept, ranibizumab, abicipar and brolucizumab. To this end, a systematic review of published randomized studies was conducted from the MEDLINE and EMBASE databases and the Cochrane library, and a meta-analysis was applied to the obtained data using single-means modeling to compare the efficacy and maintenance among the different available treatments and regimens at Years 1 and 2. Quality analysis identified the best-informed data for modeling purposes. Overall, 47 relevant publications were retrieved for the analysis. Superior efficacy, meaning that there were observed improvements in visual acuity (VA) and central retinal thickness (CRT), occurred with monthly versus PRN regimens, yet a higher IVI number was also observed. Conversely, the T&E regimens displayed similar efficacy to the monthly regimens, but with a reduced IVI number. Aflibercept T&E exhibited similar efficacy to ranibizumab T&E, but with significantly lower IVI numbers at both Year 1 (p < 0.0001) and Year 2 (p = 0.0011). Though all of the regimens resulted in maintained efficacy between Years 1 and 2, the required IVI number varied. The retrieved data did not enable other regimens or newer anti-VEGF agents such as brolucizumab to be compared. In conclusion, the T&E regimens were shown to be the most efficient, optimizing durable effectiveness whilst minimizing the IVI number in newly diagnosed exudative AMD, with aflibercept requiring the lowest IVI number.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAge-related macular degeneration (AMD)
dc.subject.enAflibercept
dc.subject.enComparative therapies
dc.subject.enEffectiveness
dc.subject.enIntravitreal anti-vascular endothelial growth factor
dc.subject.enMeta-analysis
dc.subject.enRanibizumab
dc.subject.enTreat-and-extend
dc.subject.enPro re nata regimen
dc.title.enComparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/jcm11071834en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35407439en_US
bordeaux.journalJournal of Clinical Medicineen_US
bordeaux.volume11en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Medicine&rft.date=2022-03-25&rft.volume=11&rft.issue=7&rft.eissn=2077-0383%20(Print)%202077-0383%20(Linking)&rft.issn=2077-0383%20(Print)%202077-0383%20(Linking)&rft.au=MATONTI,%20Frederic&KOROBELNIK,%20Jean-Francois&DOT,%20Corinne&GUALINO,%20Vincent&SOLER,%20Vincent&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée